Universal Antidotes for Nucleic Acid Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating the activity of nucleic acid molecules, such as aptamers, are limited by the need for sequence-specific antidotes, which can be costly and may induce inflammatory responses due to the formation of double-stranded RNA helices.
Innovation Solution
Development of 'universal antidotes' that bind nucleic acid molecules in a sequence-independent manner, using agents like protamine and polycationic polymers to inhibit or reverse their activity, avoiding the formation of double-stranded RNA helices and reducing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sequence-dependent methods are used to modulate nucleic acid activity, then specificity is improved, but complexity of development and potential for inflammatory responses increases
Solution Approach 1:
The patent applies universality by developing a single universal antidote molecule that can modulate multiple different nucleic acid therapeutics (aptamers, siRNAs, antisense oligonucleotides) through a common mechanism. This eliminates the need to develop separate reversal agents for each nucleic acid sequence, reducing development complexity while maintaining the ability to specifically bind and modulate therapeutic nucleic acids through their shared phosphate backbone structure
2Reliability
If double-stranded RNA formation is used to reverse aptamer activity, then activity reversal is achieved, but inflammatory responses are triggered
Solution Approach 1:
The patent uses an intermediary approach by introducing a universal antidote molecule that binds to therapeutic nucleic acids through electrostatic interactions with the phosphate backbone, rather than forming double-stranded RNA through base pairing. This intermediary binding mechanism achieves activity reversal without triggering the inflammatory responses associated with dsRNA formation, as the antidote does not rely on RNA-RNA hybridization
3Reliability
If customized antidote oligonucleotides are developed for each aptamer, then activity modulation is precise, but time and cost of drug development increases
Solution Approach 1:
The patent eliminates the need for customized antidote development by creating a universal antidote molecule that works across multiple nucleic acid therapeutics through sequence-independent binding. The universal antidote recognizes the common phosphate backbone structure shared by all therapeutic nucleic acids, allowing a single agent to modulate activity across different aptamers and oligonucleotide therapeutics without requiring separate development programs for each sequence
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The universal antidotes effectively and safely modulate the activity of nucleic acid molecules, offering significant time and cost savings, and providing rapid reversal of anticoagulant and antithrombotic effects, while minimizing side effects.
Implementation Method 1
agents that bind therapeutic and/or diagnostic nucleic acid molecules in a sequence independent manner
Data Source
AI summary
The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.